Global Glucagon-like Peptide-2 (GLP-2) Agonist Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 84

Published Date: 09 Jan 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Glucagon-like Peptide-2 (GLP-2) Agonist market size was valued at USD 772.7 million in 2023 and is forecast to a readjusted size of USD 2094.9 million by 2030 with a CAGR of 15.3% during review period.

Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome.

The Teduglutide market is primarily driven by the demand for innovative therapies to address short bowel syndrome (SBS) and improve the quality of life for affected patients. Teduglutide is a medication used to treat SBS, a condition characterized by impaired intestinal function due to surgical resection or congenital anomalies. The limited treatment options for SBS, coupled with advancements in gastrointestinal medicine and patient-centric care, contribute to market growth. Moreover, the demonstrated efficacy of Teduglutide in reducing dependence on parenteral nutrition and enhancing nutrient absorption further propels adoption. However, challenges include managing potential side effects and addressing patient access issues. Navigating regulatory approvals, optimizing treatment regimens, and ensuring long-term safety and efficacy are ongoing concerns. The market's success relies on continuous research in gastrointestinal disorders, collaborations between pharmaceutical manufacturers and gastroenterologists, and comprehensive patient education on the benefits and potential risks of Teduglutide treatment while addressing the evolving challenges associated with SBS management and treatment accessibility.

The Global Info Research report includes an overview of the development of the Glucagon-like Peptide-2 (GLP-2) Agonist industry chain, the market status of Hospital (Gattex, Revestive), Pharmacy (Gattex, Revestive), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Glucagon-like Peptide-2 (GLP-2) Agonist.

Regionally, the report analyzes the Glucagon-like Peptide-2 (GLP-2) Agonist markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Glucagon-like Peptide-2 (GLP-2) Agonist market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Glucagon-like Peptide-2 (GLP-2) Agonist market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Glucagon-like Peptide-2 (GLP-2) Agonist industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Gattex, Revestive).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Glucagon-like Peptide-2 (GLP-2) Agonist market.

Regional Analysis: The report involves examining the Glucagon-like Peptide-2 (GLP-2) Agonist market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Glucagon-like Peptide-2 (GLP-2) Agonist market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Glucagon-like Peptide-2 (GLP-2) Agonist:
Company Analysis: Report covers individual Glucagon-like Peptide-2 (GLP-2) Agonist manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Glucagon-like Peptide-2 (GLP-2) Agonist This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Pharmacy).

Technology Analysis: Report covers specific technologies relevant to Glucagon-like Peptide-2 (GLP-2) Agonist. It assesses the current state, advancements, and potential future developments in Glucagon-like Peptide-2 (GLP-2) Agonist areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Glucagon-like Peptide-2 (GLP-2) Agonist market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Glucagon-like Peptide-2 (GLP-2) Agonist market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
Gattex
Revestive

Market segment by Application
Hospital
Pharmacy
Other

Major players covered
Takeda Pharmaceuticals

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glucagon-like Peptide-2 (GLP-2) Agonist product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, with price, sales, revenue and global market share of Glucagon-like Peptide-2 (GLP-2) Agonist from 2019 to 2024.
Chapter 3, the Glucagon-like Peptide-2 (GLP-2) Agonist competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glucagon-like Peptide-2 (GLP-2) Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Glucagon-like Peptide-2 (GLP-2) Agonist market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Glucagon-like Peptide-2 (GLP-2) Agonist.
Chapter 14 and 15, to describe Glucagon-like Peptide-2 (GLP-2) Agonist sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Glucagon-like Peptide-2 (GLP-2) Agonist
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Gattex
        1.3.3 Revestive
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital
        1.4.3 Pharmacy
        1.4.4 Other
    1.5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size & Forecast
        1.5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity (2019-2030)
        1.5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Takeda Pharmaceuticals
        2.1.1 Takeda Pharmaceuticals Details
        2.1.2 Takeda Pharmaceuticals Major Business
        2.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product and Services
        2.1.4 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Takeda Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Glucagon-like Peptide-2 (GLP-2) Agonist by Manufacturer
    3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Manufacturer (2019-2024)
    3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Glucagon-like Peptide-2 (GLP-2) Agonist by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturer Market Share in 2023
        3.4.2 Top 6 Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturer Market Share in 2023
    3.5 Glucagon-like Peptide-2 (GLP-2) Agonist Market: Overall Company Footprint Analysis
        3.5.1 Glucagon-like Peptide-2 (GLP-2) Agonist Market: Region Footprint
        3.5.2 Glucagon-like Peptide-2 (GLP-2) Agonist Market: Company Product Type Footprint
        3.5.3 Glucagon-like Peptide-2 (GLP-2) Agonist Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region
        4.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Region (2019-2030)
        4.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Region (2019-2030)
        4.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Region (2019-2030)
    4.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value (2019-2030)
    4.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value (2019-2030)
    4.4 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value (2019-2030)
    4.5 South America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value (2019-2030)
    4.6 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2030)
    5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Type (2019-2030)
    5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2030)
    6.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Application (2019-2030)
    6.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Application (2019-2030)

7 North America
    7.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2030)
    7.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2030)
    7.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
        7.3.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Country (2019-2030)
        7.3.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2030)
    8.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2030)
    8.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
        8.3.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Country (2019-2030)
        8.3.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region
        9.3.1 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2030)
    10.2 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2030)
    10.3 South America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
        10.3.1 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Country (2019-2030)
        10.3.2 South America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
        11.3.1 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers
    12.2 Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
    12.3 Glucagon-like Peptide-2 (GLP-2) Agonist Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Glucagon-like Peptide-2 (GLP-2) Agonist and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Glucagon-like Peptide-2 (GLP-2) Agonist
    13.3 Glucagon-like Peptide-2 (GLP-2) Agonist Production Process
    13.4 Glucagon-like Peptide-2 (GLP-2) Agonist Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Glucagon-like Peptide-2 (GLP-2) Agonist Typical Distributors
    14.3 Glucagon-like Peptide-2 (GLP-2) Agonist Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 4. Takeda Pharmaceuticals Major Business
    Table 5. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product and Services
    Table 6. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 7. Takeda Pharmaceuticals Recent Developments/Updates
    Table 8. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Manufacturer (2019-2024) & (K Units)
    Table 9. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Manufacturer (2019-2024) & (USD Million)
    Table 10. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Manufacturer (2019-2024) & (USD/Unit)
    Table 11. Market Position of Manufacturers in Glucagon-like Peptide-2 (GLP-2) Agonist, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
    Table 12. Head Office and Glucagon-like Peptide-2 (GLP-2) Agonist Production Site of Key Manufacturer
    Table 13. Glucagon-like Peptide-2 (GLP-2) Agonist Market: Company Product Type Footprint
    Table 14. Glucagon-like Peptide-2 (GLP-2) Agonist Market: Company Product Application Footprint
    Table 15. Glucagon-like Peptide-2 (GLP-2) Agonist New Market Entrants and Barriers to Market Entry
    Table 16. Glucagon-like Peptide-2 (GLP-2) Agonist Mergers, Acquisition, Agreements, and Collaborations
    Table 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Region (2019-2024) & (K Units)
    Table 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Region (2025-2030) & (K Units)
    Table 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Region (2019-2024) & (USD Million)
    Table 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Region (2025-2030) & (USD Million)
    Table 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Region (2019-2024) & (USD/Unit)
    Table 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Region (2025-2030) & (USD/Unit)
    Table 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2024) & (K Units)
    Table 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2025-2030) & (K Units)
    Table 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Type (2019-2024) & (USD Million)
    Table 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Type (2025-2030) & (USD Million)
    Table 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Type (2019-2024) & (USD/Unit)
    Table 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Type (2025-2030) & (USD/Unit)
    Table 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2024) & (K Units)
    Table 30. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2025-2030) & (K Units)
    Table 31. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Application (2019-2024) & (USD Million)
    Table 32. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Application (2025-2030) & (USD Million)
    Table 33. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Application (2019-2024) & (USD/Unit)
    Table 34. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Application (2025-2030) & (USD/Unit)
    Table 35. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2024) & (K Units)
    Table 36. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2025-2030) & (K Units)
    Table 37. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2024) & (K Units)
    Table 38. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2025-2030) & (K Units)
    Table 39. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Country (2019-2024) & (K Units)
    Table 40. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Country (2025-2030) & (K Units)
    Table 41. North America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Country (2019-2024) & (USD Million)
    Table 42. North America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Country (2025-2030) & (USD Million)
    Table 43. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2024) & (K Units)
    Table 44. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2025-2030) & (K Units)
    Table 45. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2024) & (K Units)
    Table 46. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2025-2030) & (K Units)
    Table 47. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Country (2019-2024) & (K Units)
    Table 48. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Country (2025-2030) & (K Units)
    Table 49. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Country (2019-2024) & (USD Million)
    Table 50. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Country (2025-2030) & (USD Million)
    Table 51. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2024) & (K Units)
    Table 52. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2025-2030) & (K Units)
    Table 53. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2024) & (K Units)
    Table 54. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2025-2030) & (K Units)
    Table 55. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Region (2019-2024) & (K Units)
    Table 56. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Region (2025-2030) & (K Units)
    Table 57. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Region (2019-2024) & (USD Million)
    Table 58. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Region (2025-2030) & (USD Million)
    Table 59. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2024) & (K Units)
    Table 60. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2025-2030) & (K Units)
    Table 61. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2024) & (K Units)
    Table 62. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2025-2030) & (K Units)
    Table 63. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Country (2019-2024) & (K Units)
    Table 64. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Country (2025-2030) & (K Units)
    Table 65. South America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Country (2019-2024) & (USD Million)
    Table 66. South America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Country (2025-2030) & (USD Million)
    Table 67. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2019-2024) & (K Units)
    Table 68. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Type (2025-2030) & (K Units)
    Table 69. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2019-2024) & (K Units)
    Table 70. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Application (2025-2030) & (K Units)
    Table 71. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Region (2019-2024) & (K Units)
    Table 72. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity by Region (2025-2030) & (K Units)
    Table 73. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Region (2019-2024) & (USD Million)
    Table 74. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Region (2025-2030) & (USD Million)
    Table 75. Glucagon-like Peptide-2 (GLP-2) Agonist Raw Material
    Table 76. Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist Raw Materials
    Table 77. Glucagon-like Peptide-2 (GLP-2) Agonist Typical Distributors
    Table 78. Glucagon-like Peptide-2 (GLP-2) Agonist Typical Customers
List of Figures
    Figure 1. Glucagon-like Peptide-2 (GLP-2) Agonist Picture
    Figure 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value Market Share by Type in 2023
    Figure 4. Gattex Examples
    Figure 5. Revestive Examples
    Figure 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value Market Share by Application in 2023
    Figure 8. Hospital Examples
    Figure 9. Pharmacy Examples
    Figure 10. Other Examples
    Figure 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity (2019-2030) & (K Units)
    Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (2019-2030) & (USD/Unit)
    Figure 15. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Manufacturer in 2023
    Figure 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value Market Share by Manufacturer in 2023
    Figure 17. Producer Shipments of Glucagon-like Peptide-2 (GLP-2) Agonist by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
    Figure 18. Top 3 Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturer (Consumption Value) Market Share in 2023
    Figure 19. Top 6 Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturer (Consumption Value) Market Share in 2023
    Figure 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Region (2019-2030)
    Figure 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value Market Share by Region (2019-2030)
    Figure 22. North America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 23. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 24. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 25. South America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 26. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value (2019-2030) & (USD Million)
    Figure 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Type (2019-2030)
    Figure 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value Market Share by Type (2019-2030)
    Figure 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Type (2019-2030) & (USD/Unit)
    Figure 30. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Application (2019-2030)
    Figure 31. Global Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value Market Share by Application (2019-2030)
    Figure 32. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Application (2019-2030) & (USD/Unit)
    Figure 33. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Type (2019-2030)
    Figure 34. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Application (2019-2030)
    Figure 35. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Country (2019-2030)
    Figure 36. North America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value Market Share by Country (2019-2030)
    Figure 37. United States Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 38. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 39. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 40. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Type (2019-2030)
    Figure 41. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Application (2019-2030)
    Figure 42. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Country (2019-2030)
    Figure 43. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value Market Share by Country (2019-2030)
    Figure 44. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 45. France Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 46. United Kingdom Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 47. Russia Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 48. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 49. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Type (2019-2030)
    Figure 50. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Application (2019-2030)
    Figure 51. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Region (2019-2030)
    Figure 52. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value Market Share by Region (2019-2030)
    Figure 53. China Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 54. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 55. Korea Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 56. India Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 57. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 58. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 59. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Type (2019-2030)
    Figure 60. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Application (2019-2030)
    Figure 61. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Country (2019-2030)
    Figure 62. South America Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value Market Share by Country (2019-2030)
    Figure 63. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 64. Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 65. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Type (2019-2030)
    Figure 66. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Application (2019-2030)
    Figure 67. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Quantity Market Share by Region (2019-2030)
    Figure 68. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value Market Share by Region (2019-2030)
    Figure 69. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 70. Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 71. Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 72. South Africa Glucagon-like Peptide-2 (GLP-2) Agonist Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 73. Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers
    Figure 74. Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
    Figure 75. Glucagon-like Peptide-2 (GLP-2) Agonist Market Trends
    Figure 76. Porters Five Forces Analysis
    Figure 77. Manufacturing Cost Structure Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist in 2023
    Figure 78. Manufacturing Process Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist
    Figure 79. Glucagon-like Peptide-2 (GLP-2) Agonist Industrial Chain
    Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 81. Direct Channel Pros & Cons
    Figure 82. Indirect Channel Pros & Cons
    Figure 83. Methodology
    Figure 84. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Takeda Pharmaceuticals

Related Reports

Global Glucagon-like Peptide-2 (GLP-2) Agonist Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Glucagon-like Peptide-2 (GLP-2) Agonist Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 09 Jan 2023

date Pharma & Healthcare

Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome.

Global Glucagon-like Peptide-2 (GLP-2) Agonist Supply, Demand and Key Producers, 2023-2029

Global Glucagon-like Peptide-2 (GLP-2) Agonist Supply, Demand and Key Producers, 2023-2029

date 25 Feb 2023

date Pharma & Healthcare

The global Glucagon-like Peptide-2 (GLP-2) Agonist market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Glucagon-like Peptide-2 (GLP-2) Agonist Supply, Demand and Key Producers, 2024-2030

Global Glucagon-like Peptide-2 (GLP-2) Agonist Supply, Demand and Key Producers, 2024-2030

date 18 Feb 2024

date Pharma & Healthcare

The global Glucagon-like Peptide-2 (GLP-2) Agonist market size is expected to reach $ 2094.9 million by 2030, rising at a market growth of 15.3% CAGR during the forecast period (2024-2030).

Product Tags

Glucagon-like Peptide-2 (GLP-2) Agonist

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>